Clinical Trials Browser

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

400 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07190300 2026-04-08

TulmiSTAR-02

Phase 1/2 Recruiting

155 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT07287150 2026-04-08

InavoPC

Phase 2 Recruiting

100 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

479 enrolled

Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Phase 3 Recruiting

675 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Phase 2 Recruiting

218 enrolled

Genitourinary

Prostatic Neoplasms

NCT06855277 2026-02-24

AcTFirst

Phase 3 Recruiting

940 enrolled

Genitourinary

Prostatic Neoplasms

NCT07140900 2026-02-13

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Phase 1 Recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

Phase 3 Recruiting

960 enrolled

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

862 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT06520345 2025-07-10

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Phase 3 Recruiting

430 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

EvoPAR-PR02

IDeate-Prostate02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

SNV1521 in Participants With Advanced Solid Tumors

TulmiSTAR-02

InavoPC

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

AcTFirst

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

rechARge

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)